160 related articles for article (PubMed ID: 7512662)
21. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
Waehre H; Wanderaas EH; Paus E; Fosså SD
Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
[TBL] [Abstract][Full Text] [Related]
22. Indications for laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Patel MI; Katelaris PM
Aust N Z J Surg; 1995 Apr; 65(4):233-6. PubMed ID: 7536410
[TBL] [Abstract][Full Text] [Related]
23. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
24. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Stone NN; Stock RG
Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102
[TBL] [Abstract][Full Text] [Related]
25. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models.
Spevack L; Killion LT; West JC; Rooker GM; Brewer EA; Cuddy PG
Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):543-7. PubMed ID: 8621276
[TBL] [Abstract][Full Text] [Related]
26. Predicting pelvic lymph node involvement in current-era prostate cancer.
Rahman S; Cosmatos H; Dave G; Williams S; Tome M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
[TBL] [Abstract][Full Text] [Related]
27. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.
Wyler SF; Sulser T; Seifert HH; Ruszat R; Forster TH; Gasser TC; Bachmann A
Urology; 2006 Oct; 68(4):883-7. PubMed ID: 17070376
[TBL] [Abstract][Full Text] [Related]
28. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Unger P
J Urol; 1995 Oct; 154(4):1392-6. PubMed ID: 7658545
[TBL] [Abstract][Full Text] [Related]
29. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
30. Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH
AJR Am J Roentgenol; 2015 Sep; 205(3):W328-34. PubMed ID: 26295669
[TBL] [Abstract][Full Text] [Related]
31. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT.
Borley N; Fabrin K; Sriprasad S; Mondaini N; Thompson P; Muir G; Poulsen J
Scand J Urol Nephrol; 2003; 37(5):382-6. PubMed ID: 14594685
[TBL] [Abstract][Full Text] [Related]
32. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
33. Extended pelvic lymphadenectomy in patients with clinically localised prostate cancer: A prospective observational study.
Ramos JG; Caicedo JI; Cataño JG; Villarraga LG; Trujillo CG; Robledo D; Plata M
Actas Urol Esp; 2016 Sep; 40(7):446-52. PubMed ID: 26995770
[TBL] [Abstract][Full Text] [Related]
34. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
[TBL] [Abstract][Full Text] [Related]
35. Open pelvic lymph node dissection for prostate cancer: a reassessment.
Campbell SC; Klein EA; Levin HS; Piedmonte MR
Urology; 1995 Sep; 46(3):352-5. PubMed ID: 7544933
[TBL] [Abstract][Full Text] [Related]
36. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of staging lymphadenectomy in prostate cancer.
El-Galley RE; Keane TE; Petros JA; Sanders WH; Clarke HS; Cotsonis GA; Graham SD
Urology; 1998 Oct; 52(4):663-7. PubMed ID: 9763090
[TBL] [Abstract][Full Text] [Related]
38. [Radical perineal prostatectomy without lymphadenectomy. Patients with cT1 + 2, G1 +2, PSA < or = 10 ng/ml prostate carcinoma].
Jakse G; Brehmer B; Wolff JM; Aretz R; Handt S
Urologe A; 1999 Mar; 38(2):143-9. PubMed ID: 10231935
[TBL] [Abstract][Full Text] [Related]
39. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
[TBL] [Abstract][Full Text] [Related]
40. One-stage laparoscopic pelvic lymphadenectomy and radical perineal prostatectomy.
Thomas R; Steele R; Smith R; Brannan W
J Urol; 1994 Oct; 152(4):1174-7. PubMed ID: 8072087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
